Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAMAD study: Psychotherapy vs citalopram for major depression in women with breast cancer
2019-004548-31Phase 2Terminated
- Sponsor
- Cinto Segalà s
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of citalopram in major depressive disorder (MDD) (2 arms), sponsored by Cinto Segalà s. Primary endpoint: Hamilton Depression Rating Scale (HDRS) score. Started Jan 2020; status: terminated.
02
Drugs
citalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2019-004548-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004548-31.